BHWM
ONCY

Beaird Harris Wealth Management’s Oncolytics Biotech ONCY Stock Holding History

Beaird Harris Wealth Management’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-825
Closed -$754 – 528
2024
Q4 		$754 Buy
+825
New +$858 ﹤0.01% 483

Other funds holding ONCY

IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
SI
Seeds Investor New York $735M AUM 17.54% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.71B AUM 30.33% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Beaird Harris Wealth Management's ONCY Position: Q1 2025 in Review

Beaird Harris Wealth Management sold out of Oncolytics Biotech (ONCY) in Q1 2025, closing a stake of 825 shares — an estimated $754 sold.

Beaird Harris Wealth Management first reported a position in ONCY in Q4 2024 and held it in 1 quarter. The position peaked at $754 in Q4 2024. 51 funds tracked by Wall St. Rank hold ONCY as of Q1 2025.

  • Beaird Harris Wealth Management reported no remaining Oncolytics Biotech position as of Q1 2025 after selling out during the quarter.
  • Beaird Harris Wealth Management sold 825 Oncolytics Biotech shares in Q1 2025, an estimated $754.
  • Beaird Harris Wealth Management first reported a position in Oncolytics Biotech in Q4 2024 and held it in 1 quarter.
  • Beaird Harris Wealth Management's Oncolytics Biotech position peaked at $754 in Q4 2024.
  • 51 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q1 2025.

Based on Beaird Harris Wealth Management's 13F filing for Q1 2025, filed 15 May 2025.